Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis.
Yoshiya TanakaTatsuya AtsumiKazuhiko YamamotoTsutomu TakeuchiHisashi YamanakaNaoki IshiguroKatsumi EguchiAkira WatanabeHideki OrigasaToshiharu ShojiNobuyuki MiyasakaTakao KoikePublished in: International journal of rheumatic diseases (2020)
Patients with low RF and low disease activity after treatment with CZP + MTX may be able to discontinue CZP without risk of loss of response.